Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies

François Maltais1*, Anne-Marie Kirsten2, Alan Hamilton3, Dorothy De Sousa3, Florian Voß4 and Marc Decramer5

Abstract

Background: Two replicate, double-blind, placebo-controlled, 6-week crossover studies assessed the effect of the once-daily long-acting β2-agonist olodaterol 5 μg and 10 μg on constant work-rate cycle endurance in patients with moderate to very severe chronic obstructive pulmonary disease.

Methods: Patients received placebo, olodaterol 5 μg once daily (QD) and olodaterol 10 μg QD in a randomised order for 6 weeks each, with a 2-week washout period in between. The primary end point was change in endurance time during constant work-rate cycle ergometry to symptom limitation at 75% maximal work capacity after 6 weeks of treatment (2 h post-dose), based on log10-transformed data. Key secondary end points were inspiratory capacity at isotime and intensity of breathing discomfort at isotime.

Results: 151 and 157 patients were randomised and treated in Studies 1222.37 and 1222.38, respectively, with 147 and 154 being included in the full analysis sets. Mean endurance time at week 6 was increased compared to placebo by 14.0% (Study 1222.37; p < 0.001) and 11.8% (Study 1222.38; p < 0.01) with olodaterol 5 μg, and by 13.8% (Study 1222.37; p < 0.001) and 10.5% (Study 1222.38; p < 0.01) with olodaterol 10 μg. Inspiratory capacity at isotime increased with olodaterol 5 μg (Study 1222.37, 0.182 L, p < 0.0001; Study 1222.38, 0.084 L, p < 0.05) and 10 μg (Study 1222.37, 0.174 L; Study 1222.38, 0.166 L; both studies, p < 0.0001), and breathing discomfort was significantly reduced in Study 1222.37 (olodaterol 5 μg, 0.77 Borg units, p < 0.001; olodaterol 10 μg, 0.63 Borg units, p < 0.01) but not Study 1222.38.

Conclusions: These studies provide further characterisation of the efficacy of olodaterol, showing that improvements in airflow (forced expiratory volume in 1 s) are associated with increases in inspiratory capacity and improvements in exercise endurance time.

Trial registrations: NCT01040130 (1222.37) and NCT01040793 (1222.38).

Keywords: Olodaterol, Bronchodilator, Long-acting β2-agonist, COPD

* Correspondence: Francois.Maltais@fmed.ulaval.ca
1Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte Foy, Québec G1V 4G5, Canada

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Expiratory flow limitation is a hallmark of chronic obstructive pulmonary disease (COPD) [1]. During periods of increased ventilatory demand, expiratory flow limitation results in dynamic hyperinflation and is associated with significant breathing discomfort [2]. Dynamic lung hyperinflation is seen in the majority of patients with COPD during cycling [2–4] and may also be present in daily activities such as walking [5]. Hyperinflation limits exercise tolerance, which, in turn, reduces patients’ quality of life [6] and, potentially, survival [7]. As such, improving exercise tolerance is a key therapeutic goal in COPD [8].

Long-acting β₂-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are well established as maintenance therapies for moderate to very severe COPD [8, 9]. Improvements in airflow limitation with both LAMAs and LABAs are associated with increases in inspiratory capacity (IC) at rest and during exercise in patients with COPD (a marker of reduced lung hyperinflation), with resultant reductions in breathing discomfort and improvements in exercise endurance time [2, 10–17].

Olodaterol is a novel LABA with a high affinity for, and almost full intrinsic activity at, β₂ receptors, and a low affinity and partial agonist activity at β₁ receptors [18, 19]. Its duration of action is ≥24 h, allowing for once-daily (QD) dosing [20]. Pivotal Phase III trials have established the long-term efficacy of olodaterol 5 μg and 10 μg QD with respect to lung function (forced expiratory volume in 1 s [FEV₁]) [21–24].

Studies 1222.37 and 1222.38 were designed to test the hypothesis that olodaterol reduces airflow limitation during tidal breathing, reducing hyperinflation and breathing discomfort experienced during exercise, with consequent improvement in symptom-limited cycling exercise endurance.

The aim of these two replicate, 6-week, placebo-controlled, crossover studies was thus to assess the effects of olodaterol 5 μg and 10 μg QD, via the Respimat® inhaler, on constant work-rate cycling exercise endurance in patients with moderate to very severe COPD.

Methods
Patients
Patients with moderate to very severe COPD (Global initiative for chronic Obstructive Lung Disease [GOLD] 2–4) were included in the studies if they met the following inclusion criteria: persistent airway obstruction with post-bronchodilator FEV₁ <80 % of predicted normal and post-bronchodilator FEV₁/forced vital capacity [FVC] <70 %; aged 40–75 years; and with a smoking history of >10 pack-years. At variance with many COPD exercise endurance trials [2, 12–15, 17], the presence of static lung hyperinflation (i.e., increased functional residual capacity [FRC]) was not an entry requirement, since the intention of the study was to evaluate the effects of olodaterol on exercise endurance in a broad patient population. Key exclusion criteria included: a significant disease other than COPD that could influence patients’ safety during the study; history of asthma; myocardial infarction in the previous year; unstable or life-threatening cardiac arrhythmia; or hospitalisation due to heart failure in the previous year. In addition, patients were not eligible to take part if their exercise performance was limited for a reason other than fatigue or dyspnoea, such as arthritis, angina pectoris, claudication or morbid obesity, or if they had any contraindications to exercise as outlined by the European Respiratory Society Task Force on clinical exercise testing [25]. Patients with a cycling endurance time of ≥25 min at pre-randomisation evaluation were also excluded.

Study design
Studies 1222.37 (NCT01040130) and 1222.38 (NCT01040793) were replicate, multicentre, multinational, randomised, double-blind, placebo-controlled, three-way crossover trials (see Fig. 1 for a schematic of the study design). Following an initial screening visit, there was a 2-week baseline period. During the baseline period and for the rest of the trial, patients were permitted to continue with short-acting muscarinic antagonists (at least 8-h washout required prior to clinic visits), inhaled corticosteroids and xanthines, and rescue short-acting β₂-agonists (open-label salbutamol), but not LAMAs or LABAs.

Patients received each of the following treatments for 6 weeks in a randomised order: olodaterol 5 μg QD, olodaterol 10 μg QD and placebo QD. Olodaterol was administered as two actuations of the Respimat® inhaler. Between treatment periods, there was a 2-week washout period where patients continued with their permitted therapy. Clinic visits were scheduled on days 1 and 43 of each treatment period, with a follow-up visit 2 weeks after the last treatment period. In the case of early discontinuation, a follow-up visit was completed 2 weeks after the final dose of study medication.

The studies were carried out in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice, and written, informed consent was obtained from each patient.

Exercise testing
At the initial screening visit, maximum work capacity (Wcap) was determined for each patient during incremental cycle ergometry conducted as described by O’Donnell and Webb [26]. Prior to randomisation, patients performed a ‘training’ constant work-rate cycle
endurance test to symptom limitation at 75 % of Wcap and, ≥2 days later, performed a second constant work-rate cycle endurance test to determine pre-treatment baseline endurance time. Constant work-rate cycle endurance tests at 75 % Wcap were repeated on day 43 of each treatment period at 2 h (+ ≤15 min) after inhalation of the study medication. To limit the number of exercise tests performed by patients, the pre-randomisation test was used as baseline for all treatment comparisons. Intensity of breathing discomfort using the Borg category-ratio scale was recorded and IC was measured at rest, at 2-min intervals during exercise and at the end of exercise, as previously described [13]. Heart rate, blood pressure and electrocardiogram measurements were also recorded during exercise. After completing each exercise test, patients indicated the reason for stopping exercise using a simple questionnaire (due to leg and/or breathing discomfort, chest pain or other reason).

**Pulmonary function testing**

Spirometry (FEV$_1$, FVC and peak expiratory flow) was performed at screening and on days 1 and 43 of each treatment period, 30 min pre-dose (trough measurement) and 1 h post-dose.

Body plethysmography was performed on days 1 and 43 of each treatment period 30 min pre-dose (trough measurement) and 1 h post-dose (prior to spirometry), according to the methods and calibration described by Coates et al. [27] to determine FRC and IC, with total lung capacity calculated as mean FRC + largest IC of three plethysmographic measurements.

**Outcome measures**

The primary end point was log$_{10}$-transformed endurance time during constant work-rate cycle ergometry to symptom limitation at 75 % Wcap after 6 weeks of treatment. Key secondary end points were IC and intensity of breathing discomfort at isotime. Isotime was defined for each patient as the furthest exercise time that they reached in all of the constant work-rate tests (baseline and all treatment periods), i.e., their shortest ever endurance time.

In addition, two post hoc subgroup analyses were performed using combined data from Studies 1222.37 and 1222.38 to investigate exercise time in patients with static hyperinflation (FRC ≥120 % predicted) and with static and/or dynamic hyperinflation (defined as IC at rest − IC end exercise >100 mL [28]). Additional post hoc analyses (using data from the individual studies) were conducted to compare exercise time in GOLD 2 patients to GOLD 3 or 4 patients.

**Statistical analyses**

For the primary end point, adjusted means of endurance time on a log$_{10}$ scale were tested using a mixed model for repeated measures, based on previous studies showing
that endurance time has a log normal distribution [4]. The model included treatment and period as fixed effects and patient as a random effect. Log$_{10}$-transformed study baseline endurance time was added as a covariate.

Based on a predicted standard deviation of within-subject treatment difference for endurance time on a log$_{10}$ scale of ~0.181 s, with a Type I error rate of 0.05 (two-sided), 102 patients were required to detect a difference in endurance time of 15 %. Allowing for possibly higher standard deviation and patient dropout, 150 patients needed to be randomised in each study.

The primary analysis was conducted on the full analysis set, which included all patients with baseline and any evaluable post-dose endurance time data. A sensitivity analysis for the primary end point was performed based on a per-protocol set, which included patients with no significant protocol violations. No imputation was made for missing endurance time values.

Secondary analyses used the mixed model for repeated measures described above for all continuous variables but without using a log$_{10}$ scale and with non-transformed study baseline as a covariate. To calculate the IC and Borg scale values at isotime when no value was available at that exact time point, interpolation was to be used if a value was available afterwards. Missing IC or Borg scale values were imputed using last observation carried forward.

The primary and key secondary end points were included in a hierarchical testing strategy, shown in Additional file 1: Figure S1, with each test considered confirmatory only if all of the previous tests were successful. There was no alpha protection for multiple testing for the additional secondary end points.

## Results

### Patient disposition and baseline characteristics

A total of 151 patients (from 19 sites in five countries) and 157 patients (from 19 sites in five countries) were randomised into the treatment phases in Study 1222.37 and Study 1222.38, respectively (Additional file 1: Figures S2a and b). Overall, 147 (Study 1222.37) and 154 (Study 1222.38) patients were included in the full analysis set for primary analyses. At least 95 % (Study 1222.37) and 94 % (Study 1222.38) of patients in each treatment arm completed the full 6 weeks; patients who discontinued a treatment period were permitted to continue to the next treatment (Additional file 1: Figures S2a and b).

Baseline patient characteristics are shown in Table 1. Patients in Study 1222.38 had a higher baseline mean pre-bronchodilator FEV$_1$ and lower mean change from pre- to post-bronchodilator FEV$_1$ than in Study 1222.37 (Table 1). While there was no specific requirement for the presence of static lung hyperinflation at study entry, 108 (71.5 %) patients in Study 1222.37 and 116 (73.9 %) patients in Study 1222.38 did exhibit resting lung hyperinflation (FRC $\geq$120 % predicted normal at baseline) (Table 1). Relevant parameters during the baseline constant work-rate cycle test are shown in Table 2. An overview of pulmonary medication use prior to study enrolment is presented in Additional file 1: Table S1.

### Efficacy

#### Endurance time

The assumption of a log normal distribution was confirmed in both studies, with clear differences between the arithmetic mean and median endurance times at baseline and after 6 weeks of treatment in all treatment arms (Additional file 1: Table S2, Figure S3); thus the validity of the pre-specified primary analysis based on log$_{10}$-transformed endurance time was confirmed.

Log$_{10}$-transformed mean endurance time at 6 weeks significantly increased by 11.8–14.0 % with olodaterol 5 µg and by 10.5–13.8 % with olodaterol 10 µg when

| Table 1 Baseline demographics and patient characteristics (treated set*) | Study 1222.37 | Study 1222.38 |
|---|---|---|
| Male, n (%) | 116 (76.8) | 116 (73.9) |
| Mean (SD) age, years | 60.6 (7.7) | 60.6 (7.7) |
| Smoking status, n (%) | | |
| Ex-smoker | 84 (55.6) | 92 (58.6) |
| Current smoker | 67 (44.4) | 65 (41.4) |
| Mean (SD) smoking history, pack-years | 45.3 (22.5) | 50.0 (29.0) |
| FEV$_1$, L | 1.46 (0.54) | 1.56 (0.53) |
| FEV$_1$, % predicted | 48.5 (14.5) | 51.6 (14.2) |
| Mean (SD) post-bronchodilator at screening | | |
| FEV$_1$, L | 1.66 (0.55) | 1.70 (0.53) |
| FEV$_1$, % predicted | 0.19 (0.18) | 0.14 (0.19) |
| Mean (SD) pre-bronchodilator at screening | | |
| FEV$_1$, % | 55.1 (14.4) | 56.1 (13.1) |
| GOLD, n (%) | | |
| 1 (60–80 %) | 0 (0.0) | 1 (0.6)$^*$ |
| 2 (50–<60 %) | 100 (66.2) | 111 (70.7) |
| 3 (30–<50 %) | 43 (28.5) | 41 (26.1) |
| 4 (<30 %) | 8 (5.3) | 4 (2.5) |

n = 151)

*4 patients in Study 1222.37 and 3 in Study 1222.38 were included in the treated set but not the full analysis set because they did not have baseline or primary end point data; $^*$1 patient with a predicted FEV$_1$, of 80.4 %. This was classed as a protocol violation; the patient was included in the full analysis set but was excluded from the per protocol set.

SD standard deviation, FEV$_1$, forced expiratory volume in 1 s, GOLD Global Initiative for chronic Obstructive Lung Disease, FRC functional residual capacity

---

*Page 4 of 11*
Table 2 Baseline exercise parameters (full analysis set)

| Study            | Study 1222.37 (n = 147) | Study 1222.38 (n = 154) |
|------------------|--------------------------|-------------------------|
| Geometric mean (SE) endurance time, s | 414.2 (18.5) | 373.9 (13.5) |
| Arithmetic mean (SE) endurance time, s | 478.2 (21.9) | 415.5 (17.4) |
| Mean (SE) IC, L  |                          |                         |
| Pre-exercise     | 2.29 (0.06)              | 2.37 (0.06)             |
| Isotime          | 2.04 (0.07)              | 2.14 (0.06)             |
| End-exercise     | 2.00 (0.06)              | 2.13 (0.06)             |
| Mean (SE) breathing discomfort, Borg units | 0.32 (0.05) | 0.31 (0.05) |
| Pre-exercise     | 5.27 (0.21)              | 5.53 (0.19)             |
| Isotime          | 7.20 (0.20)              | 7.51 (0.18)             |
| End-exercise     | 0.26 (0.07)              | 0.18 (0.04)             |
| Mean (SE) leg discomfort, Borg units | 0.26 (0.07) | 0.18 (0.04) |
| Pre-exercise     | 5.27 (0.22)              | 4.42 (0.22)             |
| Isotime          | 7.05 (0.23)              | 6.01 (0.24)             |
| Locus of symptom limitation, n (%) |                          |                         |
| Breathing discomfort | 52 (35.4) | 81 (52.6) |
| Leg discomfort   | 40 (27.2)                | 26 (16.9)               |
| Breathing and leg discomfort | 52 (35.4) | 42 (27.3) |
| None             | 3 (2.0)                  | 5 (3.2)                 |

SE standard error, IC inspiratory capacity

compared to placebo (Fig. 2). Arithmetic and geometric mean endurance times are shown in Additional file 1: Table S2.

There were no significant differences in endurance time between olodaterol 5 µg and 10 µg for the primary end point in either study. The results of the per-protocol set analysis were consistent with the primary analysis.

Changes in endurance time in patients who were GOLD 2 and patients who were GOLD 3 or 4 are shown in Additional file 1: Table S3. There were generally slightly higher increases in endurance time with olodaterol in GOLD 3/4 patients than in GOLD 2 patients.

In patients from Studies 1222.37 and 1222.38 with static hyperinflation at baseline (FRC ≥120 % predicted normal; n = 224), log₁₀-transformed mean endurance time at 6 weeks significantly increased by 13.2 % (p < 0.0001) and 12.2 % (p = 0.0002) with olodaterol 5 µg and 10 µg, respectively, from a geometric mean baseline endurance time of 376.4 s. In a subgroup of patients from both studies with static and/or dynamic hyperinflation (defined as IC at rest – IC end exercise >100 mL [28]; n = 274), log₁₀ mean endurance time increased from geometric mean baseline of 388.2 s by 13.3 % (p < 0.0001) and 12.1 % (p < 0.0001) with olodaterol 5 µg and 10 µg, respectively. These improvements were of similar magnitude to those observed in the whole population of patients.

IC and breathing discomfort

In both studies, IC increased with olodaterol 5 µg and 10 µg at rest (prior to exercise), at isotime and at end-exercise (Fig. 3). There was a statistically significant increase in IC at isotime compared to placebo with olodaterol 5 µg (0.182 L; p < 0.0001) and 10 µg (0.174 L; p < 0.0001) in Study 1222.37, and with olodaterol 5 µg (0.084 L; p < 0.05) and 10 µg (0.166 L; p < 0.0001) in Study 1222.38 (Fig. 3).

There was a significant reduction in the intensity of breathing discomfort at isotime compared to placebo in Study 1222.37 of 0.77 Borg units with olodaterol 5 µg (p < 0.001) and 0.63 Borg units with olodaterol 10 µg (p < 0.01); there were no significant differences in Study 1222.38 (Table 3).

Spirometry and body plethysmography

In both studies, FEV₁ and FVC significantly improved at trough (30 min pre-dose) and at 1 h post-dose with olodaterol 5 µg and 10 µg compared to placebo (Table 4). Peak expiratory flow data are shown in Additional file 1: Table S4.

Both studies showed statistically significant increases in IC measured using body plethysmography for olodaterol 5 µg and 10 µg compared to placebo at 30 min pre-dose and 1 h post-dose, with corresponding decreases in FRC (Table 5). The results of IC at 1 h post-dose using body plethysmography (Table 5) were similar to the results of IC 2 h post-dose measured using spirometry immediately prior to exercise (Fig. 3).

Safety and tolerability

Adverse events

Across both studies, incidences of adverse events, serious adverse events and adverse events leading to discontinuation with olodaterol 5 µg and 10 µg were similar to placebo (Table 6). The most common adverse event was COPD exacerbation, occurring in 6.7–7.0 %, 6.0–7.5 % and 2.7–4.9 % of patients with placebo, olodaterol 5 µg and olodaterol 10 µg, respectively, in both studies. Three patients in each treatment group in Study 1222.37 and three patients in the placebo group, eight with olodaterol 5 µg and three with olodaterol 10 µg in Study 1222.38 had serious adverse events. None of the serious adverse events in Study 1222.37 and one in Study 1222.38 (atrial fibrillation in a patient taking olodaterol 5 µg) were considered by the investigator to be related to the study drug.

There were no clinically relevant changes in laboratory parameters, vital signs or electrocardiogram in either study. There were no deaths in Study 1222.37 and one death of unknown cause after 5 days of treatment in the olodaterol 10 µg group in Study 1222.38.
Discussion

Results from these two replicate trials confirm that treatment with olodaterol improves exercise endurance time during constant work-rate cycle ergometry in patients with COPD. The improvements in endurance time were observed in patients with a broad range of disease characteristics, including GOLD 2 patients with moderate disease (69 % of the total patient population) and patients with and without static lung hyperinflation (89 % of the total patient population), supporting the application of our results to a larger COPD population. There were no differences in endurance time between patients receiving olodaterol 5 \( \mu \)g and 10 \( \mu \)g, and both doses were well tolerated. The improved endurance time with olodaterol was associated with an increase in IC that was present at rest (prior to exercise) and was maintained during exercise, which has also been observed with other bronchodilators [13].

Since early exercise studies of tiotropium in patients with COPD [13, 15], constant work-rate exercise protocols to symptom limitation, with serial measurements of IC and breathing discomfort, have frequently been used to investigate the effects of long-acting bronchodilators on lung hyperinflation, exertional dyspnoea and symptom-limited exercise capacity [12, 14, 15, 17, 29–31] (NCT01533922 and NCT01533935; manuscript in preparation). The consistent demonstration of a significant relationship between IC and endurance time [13] has led to an increased understanding of the mechanistic relationship between the primary effects of bronchodilators in improving expiratory flow, and the consequent reductions in lung hyperinflation and exertional breathing discomfort, which in turn lead to increases in the time to reach intolerable symptom intensity during exercise.

An important methodological consideration in relation to the current trials is that statistical analyses were performed on log_{10}-transformed endurance time data, unlike previous trials that have assessed cycling endurance time in COPD. Although these analyses are justified by the fact that endurance time during constant work-rate exercise is asymmetrically distributed around the mean, with a significant skew towards long exercise endurance times (as has been previously reported [4] and confirmed in the present trials), this approach complicates comparisons with previous trials. For the purpose of facilitating comparisons across studies, we also report the arithmetic mean treatment effects of olodaterol (Additional file 1: Table S2). The arithmetic differences in endurance time for olodaterol, compared to placebo, range from 40 to 64 s. Although these may appear to be at the lower end of what is typically reported with other long-acting bronchodilators, including tiotropium, glycopyrronium bromide, aclidinium bromide, salmeterol and indacaterol [12, 14, 15, 17, 29, 30], they are within the estimated range for a clinically meaningful difference, compared to
Fig. 3 Adjusted mean inspiratory capacity after 6 weeks in (a) Study 1222.37 and (b) Study 1222.38 (full analysis set). SE standard error.
placebo, of 46–105 s for endurance time, as proposed by the European Respiratory Society task force on outcomes in COPD [32]. Caution should be exercised when comparing increases in endurance time across studies due to a number of confounding factors, including differences in patient characteristics and phenotypes. Variation in the improvement in expiratory flow following bronchodilation from one study population to another may contribute to the observed differences in effect size between studies. In light of this, an important methodological difference between our studies and previous exercise trials was that the presence of static lung hyperinflation was not a prerequisite for participation in our trials. Also at variance with previous trials [13, 15], patients with post-bronchodilator FEV\textsubscript{1} ≤ 80 % predicted were permitted in our trials, including a larger proportion of GOLD 2 patients (69 % of the total patient population). Although olodaterol also enhanced exercise capacity in these patients, the inclusion of patients with milder COPD may have mitigated the observed differences in effect size between studies. In light of this, an important methodological difference between our studies and previous exercise trials was that the presence of static lung hyperinflation was not a prerequisite for participation in our trials. Also at variance with previous trials [13, 15], patients with post-bronchodilator FEV\textsubscript{1} ≤ 80 % predicted were permitted in our trials, including a larger proportion of GOLD 2 patients (69 % of the total patient population). Although olodaterol also enhanced exercise capacity in these patients, the inclusion of patients with milder COPD may have mitigated the observed differences in effect size between studies.

### Table 3

Adjusted mean breathing discomfort measured using the Borg category-ratio scale at isotime after 6 weeks (full analysis set)

| Treatment          | n  | Mean time, mm:ss* | Borg (SE)  | p value versus placebo |
|--------------------|----|------------------|------------|------------------------|
| Study 1222.37      |    |                  |            |                        |
| Baseline           | 136| 05:58            | 5.27 (0.21) |                        |
| Placebo            | 136| 05:58            | 5.87 (0.19) |                        |
| Olodaterol 5 μg    | 140| 06:02            | 5.10 (0.18) | 0.0007                 |
| Olodaterol 10 μg   | 136| 06:05            | 5.24 (0.19) | 0.0051                 |
| Study 1222.38      |    |                  |            |                        |
| Baseline           | 146| 05:29            | 5.53 (0.19) |                        |
| Placebo            | 146| 05:29            | 5.59 (0.18) |                        |
| Olodaterol 5 μg    | 141| 05:25            | 5.25 (0.18) | 0.1176                 |
| Olodaterol 10 μg   | 140| 05:22            | 5.52 (0.18) | 0.7591                 |

*Due to differences in the number of patients between treatment groups, slight differences in mean time are observed

### Table 4

Adjusted mean FEV\textsubscript{1} and FVC outcomes at 6 weeks (full analysis set)

| Treatment          | Planned time (min) | FEV\textsubscript{1} | Mean (SE) L | Mean (SE) difference from placebo | p value | FVC | Mean (SE) L | Mean (SE) difference from placebo | p value |
|--------------------|--------------------|----------------------|-------------|-----------------------------------|---------|-----|-------------|-----------------------------------|---------|
| Study 1222.37      |                    |                      |             |                                   |         |     |             |                                   |         |
| Placebo            | −0.30 (pre-dose/trough) | 1.475 (0.017)*a      | 3.212 (0.037)*b |                                   |         |     | 3.19 (0.037)*a | 0.107 (0.031) | 0.0006 |
| Olodaterol 5 μg    | 1.564 (0.017)*c      | 0.089 (0.017)        | <0.0001     | 3.10 (0.037)*a                    | 0.098 (0.031) | 0.0017 |
| Olodaterol 10 μg   | 1.576 (0.017)*d      | 0.101 (0.017)        | <0.0001     | 3.10 (0.037)*a                    | 0.107 (0.031) | 0.0006 |
| Placebo            | 1.473 (0.019)*a      |                      | 3.187 (0.034)*b |                                   |         |     |             |                                   |         |
| Olodaterol 5 μg    | 1.698 (0.019)*c      | 0.224 (0.017)        | <0.0001     | 3.47 (0.034)*a                    | 0.285 (0.029) | <0.0001 |
| Olodaterol 10 μg   | 1.699 (0.019)*e      | 0.226 (0.017)        | <0.0001     | 3.47 (0.034)*a                    | 0.290 (0.029) | <0.0001 |
| Study 1222.38      |                    |                      |             |                                   |         |     |             |                                   |         |
| Placebo            | −0.30 (pre-dose/trough) | 1.512 (0.024)*a      | 3.102 (0.019)*d |                                   |         |     | 3.103 (0.039)*d | 0.119 (0.036) | 0.0013 |
| Olodaterol 5 μg    | 1.630 (0.025)*a      | 0.110 (0.019)        | <0.0001     | 3.22 (0.040)*a                    | 0.119 (0.037) | 0.0013 |
| Olodaterol 10 μg   | 1.630 (0.025)*a      | 0.110 (0.019)        | <0.0001     | 3.22 (0.040)*a                    | 0.119 (0.037) | 0.0013 |
| Placebo            | 1.577 (0.026)*a      |                      | 3.144 (0.039)*d |                                   |         |     |             |                                   |         |
| Olodaterol 5 μg    | 1.768 (0.026)*a      | 0.192 (0.021)        | <0.0001     | 3.40 (0.040)*a                    | 0.265 (0.035) | <0.0001 |
| Olodaterol 10 μg   | 1.771 (0.026)*a      | 0.195 (0.021)        | <0.0001     | 3.42 (0.040)*a                    | 0.281 (0.035) | <0.0001 |

*\(n = 136; x^n = 135; \#n = 137; ^{\#\#}n = 146; ^{*}\#n = 143; ^{\#\#\#}n = 139 \)

Common baseline means (SE): Study 1222.37, FEV\textsubscript{1}, 1.478 (0.043); FVC, 3.221 (0.073). Study 1222.38, FEV\textsubscript{1}, 1.553 (0.043); FVC, 3.160 (0.072)

SE standard error, FEV\textsubscript{1}, forced expiratory volume in 1 s, FVC forced vital capacity
effect sizes of the study medication on exercise capacity to some extent.

The multifactorial nature of exercise limitation in patients with COPD may also contribute to the variability in exercise response to bronchodilators from one study to another. This phenomenon is illustrated by the results of replicate studies with tiotropium [13, 15], in which similar lung-function improvements resulted in notable differences in the magnitude of improvement in endurance time, varying from 21 % in the first study to 40 % in the second study.

### Table 5 Adjusted mean body plethysmography outcomes at 6 weeks: IC and FRC (full analysis set)

| Treatment       | Planned time (min) | n<sup>a</sup> | IC  | Mean (SE) IC, L    | Mean (SE) difference from placebo, L | p value | FRC  | Mean (SE) FRC, L     | Mean (SE) difference from placebo, L | p value |
|-----------------|--------------------|---------------|-----|--------------------|-------------------------------------|---------|------|---------------------|-------------------------------------|---------|
| **Study 1222.37** |                    |               |     |                    |                                     |         |      |                     |                                     |         |
| Placebo         | −30 (pre-dose/trough) | 134-135      | IC  | 2.170 (0.040)      |                                     |         |      | 4.977 (0.062)       |                                     |         |
| Olodaterol 5 μg | 139-140            | 134-140      | IC  | 2.289 (0.040)      | 0.119 (0.034)                      | 0.0005  |      | 4.855 (0.061)       | −0.122 (0.069)                      | 0.0784  |
| Olodaterol 10 μg| 134                | 134-135      | IC  | 2.262 (0.040)      | 0.092 (0.034)                      | 0.0073  |      | 4.862 (0.062)       | −0.115 (0.070)                      | 0.1013  |
| Placebo         | 60 (post-dose)     | 134-135      | IC  | 2.221 (0.040)      |                                     |         |      | 4.950 (0.064)       |                                     |         |
| Olodaterol 5 μg | 139-140            | 134-140      | IC  | 2.427 (0.040)      | 0.206 (0.035)                      | <0.0001 |      | 4.740 (0.063)       | −0.210 (0.066)                      | 0.0015  |
| Olodaterol 10 μg| 134                | 134-135      | IC  | 2.437 (0.040)      | 0.216 (0.036)                      | <0.0001 |      | 4.577 (0.064)       | −0.373 (0.066)                      | <0.0001 |
| **Study 1222.38** |                    |               |     |                    |                                     |         |      |                     |                                     |         |
| Placebo         | −30 (pre-dose/trough) | 147          | IC  | 2.463 (0.041)      |                                     |         |      | 4.842 (0.062)       |                                     |         |
| Olodaterol 5 μg | 145-146            | 143          | IC  | 2.613 (0.041)      | 0.150 (0.040)                      | 0.0002  |      | 4.757 (0.063)       | −0.086 (0.053)                      | 0.1048  |
| Olodaterol 10 μg| 141-142            | 143          | IC  | 2.618 (0.042)      | 0.154 (0.040)                      | 0.0001  |      | 4.723 (0.063)       | −0.120 (0.053)                      | 0.0246  |
| Placebo         | 60 (post-dose)     | 147          | IC  | 2.493 (0.040)      |                                     |         |      | 4.770 (0.065)       |                                     |         |
| Olodaterol 5 μg | 145-146            | 143          | IC  | 2.725 (0.040)      | 0.232 (0.036)                      | <0.0001 |      | 4.557 (0.065)       | −0.213 (0.053)                      | <0.0001 |
| Olodaterol 10 μg| 141-142            | 143          | IC  | 2.696 (0.040)      | 0.203 (0.036)                      | <0.0001 |      | 4.583 (0.065)       | −0.187 (0.054)                      | 0.0005  |

<sup>a</sup>N numbers for IC and FRC

IC inspiratory capacity, FRC forced residual capacity, SE standard error

### Table 6 Common adverse events<sup>b</sup> (treated set<sup>c</sup>)

| Study          | Placebo 5 μg | Placebo 10 μg | Olodaterol 5 μg | Olodaterol 10 μg | Olodaterol 5 μg | Olodaterol 10 μg |
|----------------|--------------|---------------|-----------------|------------------|-----------------|------------------|
| **Study 1222.37** | 38 (26.6)   | 42 (29.4)     | 49 (33.3)       | 42 (29.4)        | 34 (22.8)       | 42 (28.0)        |
| **Study 1222.38** | 34 (22.8)   | 42 (28.0)     | 49 (33.3)       | 42 (29.4)        | 34 (22.8)       | 42 (28.0)        |

<sup>b</sup>With incidence ≥ 2 %;<sup>c</sup> 4 patients in Study 1222.37 and 3 in Study 1222.38 were included in the treated set but not the full analysis set because they did not have baseline or primary end point data

COPD chronic obstructive pulmonary disease

---

Maltais et al. Respiratory Research (2016) 17:77
An unexpected finding in the present studies was the reduction in endurance time in the placebo group after 6 weeks of treatment, compared to pre-randomisation baseline, which has not been observed in previous studies. Whether this was a reflection of a time-dependent decrease in exercise capacity over the 23-week observation period or a deterioration related to the lack of optimal bronchodilatation in the placebo group is difficult to ascertain because only a single, pre-randomisation baseline exercise test was included to limit the burden on study participants. However, the concomitant reduction in IC that was also observed prior to exercise in the placebo group would argue for the latter explanation. A reduction in post-treatment exercise endurance, compared to pre-randomisation baseline, was also observed in the placebo groups of two recently completed, replicate, 6-week, crossover trials of similar design (NCT01533922 and NCT01533935; manuscript in preparation), while in a 12-week, parallel-group, exercise study, exercise endurance time in the placebo group was reduced after 6 weeks, but increased after 12 weeks, compared to baseline (NCT01525615; manuscript in preparation).

Conclusions
These two studies demonstrated that olodaterol 5 µg and 10 µg both improved exercise endurance time after 6 weeks of treatment compared to placebo, likely as a consequence of reductions in hyperinflation prior to exercise, which were maintained during exercise.

Additional file

Additional file 1: Table S1. Pulmonary medication use prior to enrolment (treated set). Table S2. Arithmetic mean, geometric mean and median endurance times after 6 weeks (full analysis set). Table S3. Geometric mean (SE) endurance time after 6 weeks by GOLD (full analysis set). Table S4. Peak expiratory flow outcomes at 6 weeks (full analysis set). Figure S1. Hierarchical testing order: each test was considered confirmatory only if all of the previous tests were positive.

Figure S2. Participant flow in (a) Study 1222.37 and (b) Study 1222.38.

Figure S3. Exercise endurance time after 6 weeks for (a) Study 1222.37 and (c) Study 1222.38. Log_10 transformation of exercise endurance time after 6 weeks for (b) Study 1222.37 and (d) Study 1222.38 (full analysis set). (DOCX 631 kb)

Abbreviations
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FRC, functional residual capacity; FVC, forced vital capacity; GOLD, Global initiative for Chronic Obstructive Lung Disease; IC, inspiratory capacity; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; QD, once daily; Wcap, maximum work capacity

Acknowledgements
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. They take full responsibility for the scope, direction, content of, and editorial decisions relating to, the manuscript, were involved at all stages of development and have approved the submitted manuscript. Medical writing assistance was provided by Claire Scofield, MRes, and Lianne Young, BSc (Hons), of Complete HealthVizion, which was contracted and compensated by Boehringer Ingelheim Pharma GmbH & Co. KG.

Authors’ contributions
FM and MD are the principal investigators in the 1222.37 and 1222.38 trials, respectively. FV is the statistician for the trials. AH and DDS were involved in the design of the study and are involved in the implementation of the study. All authors were involved in reviewing and critiquing this paper. The authors received no compensation related to the development of the manuscript. All authors read and approved the final manuscript.

Competing interests
This work was supported by Boehringer Ingelheim Pharma GmbH & Co. KG. FM has participated in advisory boards for Boehringer Ingelheim, holds a CIHR/GlaxoSmithKline research Chair on COPD at Université Laval, has received consultation fees from Boehringer Ingelheim and lecture fees from Boehringer Ingelheim, AstraZeneca and Novartis, and his institution has received grants from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Nycomed and Novartis. A-MK has received lecture fees from Boehringer Ingelheim, Novartis and AstraZeneca, and compensation for clinical study conduct from Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Chiesi, Takeda, AB2 Bio, Bayer, Intermune, Roche, Johnson & Johnson, Infinity and Sterna Biologicals. AH, DDS and FV are employees of Boehringer Ingelheim. MD has participated in advisory boards for Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Nycomed and Altana, and received consultancy and lecture fees from Boehringer Ingelheim, Pfizer, GlaxoSmithKline, Nycomed, Dompé and Novartis, and a grant from AstraZeneca.

Author details
1Centre de Recherche, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte Foy, Québec G1V 4G5, Canada. 2Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Grosshansdorf, Germany. 3Boehringer Ingelheim, Burlingon, ON, Canada. 4Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. 5Department of Pulmonology, University Hospitals Leuven, Leuven, Belgium.

Received: 3 February 2016 Accepted: 6 June 2016
Published online: 06 July 2016

References
1. O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Macniniuk DD, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J. 2007;14(Suppl B):S8–S32.
2. Verkinder C, Bart F, Aguilaniu B, Fortin F, Guérin J-C, Le Mère C, et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respira. 2006;73:420–7.
3. O’Donnell DE. Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exerc. 2001;33(Suppl):S647–55.
4. O’Donnell DE, Travers J, Webb KA, He Z, Lam Y-M, Hamilton A, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J. 2002;19(Suppl):S666–74.
5. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1395–9.
6. Esteban C, Quintana JM, Aburto M, Moraza J, Egurrola M, Pérez-Izquierdo J, et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J. 2010;36:292–300.
7. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Role of exercise capacity and health status. Am J Respir Crit Care Med. 2003;167:544–9.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2016. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed 27 Apr 2016.
9. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res. 2013;14:49.
10. O’Donnell DE, Casaburi R, Vincken W, Puente-Maestu L, Svalnes J, Lawrence D, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med. 2011;105:1030-6.

11. Liesker JW, Wijkstra PJ, ten Hacken NHT, Koeter GH, Postma DS, Kerstjens HAM. A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD. Chest. 2002;121:597–608.

12. O’Donnell DE, Vodic N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J. 2004;24:486–94.

13. O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:382–40.

14. O’Donnell DE, Sciruba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647–56.

15. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciruba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with severe COPD. Chest. 2005;128:1168–78.

16. Neder JA, Fuld JP, Overend T, Thillwell J, Carter R, Stevenson R, et al. Effects of long-acting β2-agonist on exercise tolerance in severely disabled patients with COPD. Respir Med. 2007;101:2056–64.

17. Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, et al. Acidolinum bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir Med. 2011;105:580–7.

18. Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010;334:53–62.

19. Casarosa P, Kollak I, Kiechle T, Ostermann A, Schnapp A, Kiesling R, et al. Functional and biochemical rationales for the 24-hour-long duration of action of olodaterol. J Pharmacol Exp Ther. 2011;337:600–9.

20. Joos GF, Aumann J-L, Coeck C, Korducki L, Hamilton AL, Kunz C, et al. A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109:606–15.

21. Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, et al. Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629–45.

22. Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:697–714.

23. Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C. The 24-h FEV1 profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2–4 COPD: results from two 6-week crossover studies. Springerplus. 2014;3:419.

24. Lange P, Aumann J-L, Hamilton A, Tetzlaff K, Ting N, Derom E. The 24 hour lung function time profile of olodaterol once daily versus placebo and tiotropium in patients with moderate to very severe chronic obstructive pulmonary disease. J Pulm Respir Med. 2014;11:196.

25. ERS Task Force on Standardization of Clinical Exercise Testing. Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J. 1997;10:2662–89.

26. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148:1351–2.

27. Coates AL, Peslin R, Rodenstein D, Stocks J. Measurement of lung volumes by plethysmography. Eur Respir J. 1997;10:1415–27.

28. Casaburi R, Maltais F, Porszasz J, Albers F, Deng Q, Iqbal A, et al. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1351–61.

29. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503–13.

30. Borel B, Provencher S, Saeys D, Maltais F. Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med. 2013;2013:410748.

31. Beeh K-M, Kom S, Beier J, Jadayel D, Henley M, D’Andrea P, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584–92.

32. Cazzola M, MacNee W, Martinez FJ, Rabé RF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–69.